Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network - PubMed
2 days ago
- #Obesity
- #Semaglutide
- #Heart failure
- Study compares semaglutide and tirzepatide in patients with obesity and HFpEF.
- Both drugs showed similar risks for the primary composite endpoint (all-cause mortality and HF hospitalization).
- No significant differences were observed in individual components of the primary endpoint (all-cause death and HF hospitalization).
- Results were consistent regardless of diabetes status.
- The study utilized a non-randomized, observational cohort design with data from the TriNetX Global Collaborative Research Network.
- Median follow-up was 24 weeks with a mean age of 66 years and mean BMI of 42 kg/m² among participants.